PARP Inhibitors in Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: closed (20 December 2023) | Viewed by 3891
Special Issue Editors
Interests: PARP; hypoxia; tumor microenvironment; PARP inhibitor; mitochondrial diseases
2. Laboratory of Immunology, Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain
Interests: PARP; DNA damage; tumor cell; immune response
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The deeper understanding of DNA repair mechanisms and their potential value as therapeutic targets in oncology heralded the clinical development of a wide range of chemical inhibitors, targeting several enzymes working on signal DNA damage, modulating chromatin architecture or inhibiting specific DNA repair pathways, whose activity was certainly uncontrolled in cancer cells. Poly (ADP-ribose) polymerase (PARP) inhibitors represent a novel and effective class of anti-cancer therapy, highlighting the importance of the synthetic lethality concept in cancer progression, focusing on cells lacking homologous recombination DNA repair. Biochemically, PARP inhibition leads to the accumulation of DNA damage by impairing single-strand break sites, trapping DNA-dependent PARP at these SSBR sites and leading to the inhibition of DNA replication.
However, the mechanism is much more complex and the biology of PARP enzymes inhibition is still far from fully understood. This misinformation has triggered a multitude of projects and groups that have opened new lines of research in cancer, neurodegenerative diseases, metabolic or cardiac diseases, enriching knowledge about the therapeutic potential of PARP inhibitors.
This Special Issue welcomes both original research manuscripts as well as reviews focusing on the current state of PARP inhibitors in cancer therapy.
Dr. Jose Manuel Rodriguez-Vargas
Dr. José Yélamos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PARP inhibitors
- clinical relevance
- cancer progression
- DNA repair mechanisms
- cancer cells
